Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

(marketscreener.com) New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021ANDOVER, Mass., Oct. 07, 2022 -- Oncorus, Inc. , a viral immunotherapies company focused on stimulating the immune system to transform outcomes for cancer patients, today announced the publication of preclinical data in...https://www.marketscreener.com/quote/stock/ONCORUS-INC-113170571/news/Oncorus-Announces-Publication-in-Nature-Communications-Highlighting-the-Development-of-its-Intraveno-41951897/?utm_medium=RSS&utm_content=20221007